Control of infection following burn injury.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002056:Burns / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D002404:Catheterization / Q000009:adverse effects; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D011552:Pseudomonas Infections / Q000276:immunology; D012141:Respiratory Tract Infections / Q000209:etiology / Q000401:mortality; D018805:Sepsis / Q000209:etiology; D012835:Silver Nitrate / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000276:immunology; D013290:Streptococcal Infections / Q000276:immunology; D013411:Sulfadiazine / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000209:etiology / Q000401:mortality; D014946:Wound Infection / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D013449:Sulfonamides; D013411:Sulfadiazine; D012835:Silver Nitrate